Our client, a multinational mid-sized pharma company headquartered in India needed an end-to-end clinical trial partner to evaluate a randomized, open label, 8-treatment arm clinical trial to evaluate the safety and efficacy of four marketed drugs in the acute treatment of COVID-19 patients.
Read our latest case study and learn how we are driving operational approaches to evaluate the safety and efficacy of their therapies in moderate COVID-19 patients. From being awarded the studies to date we have:
- Quickly activated sites within 20 days
- Achieved FPI within 28 days of study award
- Accomplished 100% on-time completion of key milestones
- Comprehensive trial oversight through our in-house analytics platform
Please complete the form to download our case study.